No/DT
Association/NN
between/IN
Copy/NN
Number/NN
Variation/NN
of/IN
the/DT
TCRB/NN
Gene/NN
and/CC
the/DT
Risk/NN
of/IN
Autism/NN
Spectrum/NN
Disorder/NN
in/IN
the/DT
Korean/JJ
Population/NN
./.
====================
Although/IN
autism/NN
spectrum/NN
disorder/NN
(/(
ASD/NN
)/)
has/VBZ
been/VBN
thought/VBN
to/TO
have/VB
a/DT
substantial/JJ
genetic/JJ
background/NN
,/,
major/JJ
contributing/VBG
genes/NNS
have/VBP
yet/RB
to/TO
be/VB
identified/VBN
or/CC
successfully/RB
replicated/VBN
./.
====================
Immunological/JJ
dysfunction/NN
has/VBZ
been/VBN
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
ASD/NN
,/,
and/CC
T/NN
cellmediated/JJ
immunity/NN
was/VBD
considered/VBN
important/JJ
for/IN
the/DT
development/NN
of/IN
ASD/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyzed/VBD
163/CD
ASD/NN
subjects/NNS
and/CC
97/CD
normal/JJ
controls/NNS
by/IN
genomic/JJ
quantitative/JJ
PCR/NN
to/TO
evaluate/VB
the/DT
association/NN
between/IN
the/DT
copy/NN
number/NN
variation/NN
of/IN
the/DT
7q34/NN
locus/NN
,/,
harboring/VBG
the/DT
TCRB/NN
gene/NN
,/,
and/CC
ASDs/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
there/EX
was/VBD
no/DT
significant/JJ
difference/NN
of/IN
the/DT
frequency/NN
distribution/NN
of/IN
TCRB/NN
copy/NN
numbers/NNS
between/IN
ASD/NN
cases/NNS
and/CC
normal/JJ
controls/NNS
./.
====================
TCRB/NN
gene/NN
copy/NN
numbers/NNS
ranged/VBD
from/IN
0/CD
to/TO
5/CD
copies/NNS
,/,
and/CC
the/DT
frequency/NN
distribution/NN
of/IN
each/DT
copy/NN
number/NN
was/VBD
similar/JJ
between/IN
the/DT
two/CD
groups/NNS
./.
====================
The/DT
proportion/NN
of/IN
the/DT
individuals/NNS
with/IN
＜2/NN
copies/NNS
of/IN
TCRB/NN
was/VBD
52.8/CD
%/NN
(/(
86/163/CD
)/)
in/IN
ASD/NN
cases/NNS
and/CC
57.1/CD
%/NN
(/(
52/91/CD
)/)
in/IN
the/DT
control/NN
group/NN
(/(
p=0.44/NN
)/)
./.
====================
The/DT
proportion/NN
of/IN
individuals/NNS
with/IN
＞2/NN
copies/NNS
of/IN
TCRB/NN
was/VBD
11.7/CD
%/NN
(/(
19/163/CD
)/)
in/IN
ASD/NN
cases/NNS
and/CC
12.1/NN
%/NN
(/(
11/91/CD
)/)
in/IN
the/DT
control/NN
group/NN
(/(
p=0.68/NN
)/)
./.
====================
After/IN
the/DT
effects/NNS
of/IN
sex/NN
were/VBD
adjusted/VBN
by/IN
logistic/JJ
regression/NN
,/,
ORs/NNS
for/IN
individuals/NNS
with/IN
＜2/NN
copies/NNS
or/CC
＞2/NN
copies/NNS
showed/VBD
no/DT
significant/JJ
difference/NN
compared/VBN
with/IN
the/DT
diploid/JJ
copy/NN
number/NN
as/IN
reference/RB
(/(
n=2/NN
)/)
./.
====================
Although/IN
we/PRP
could/MD
not/RB
see/VB
the/DT
positive/JJ
association/NN
,/,
our/PRP$
results/NNS
will/MD
be/VB
valuable/JJ
information/NN
for/IN
mining/JJ
ASD-associated/JJ
genes/NNS
and/CC
for/IN
exploring/VBG
the/DT
role/NN
of/IN
T/NN
cell/NN
immunity/NN
further/RBR
in/IN
the/DT
pathogenesis/NN
of/IN
ASD/NN
./.
====================
Autism/NN
spectrum/NN
disorders/NNS
(/(
ASDs/NNS
)/)
are/VBP
complex/NN
neurodevelopmental/JJ
disorders/NNS
with/IN
the/DT
core/NN
features/NNS
of/IN
impairment/JJ
in/IN
social/JJ
interaction/NN
and/CC
verbal/JJ
communication/NN
and/CC
repetitive/JJ
or/CC
stereotyped/JJ
patterns/NNS
in/IN
behavior/NN
./.
====================
These/DT
disorders/NNS
typically/RB
manifest/VBP
within/IN
the/DT
first/JJ
three/CD
years/NNS
of/IN
life/NN
(/(
Klauck/NN
,/,
2006/CD
)/)
./.
====================
The/DT
etiology/NN
of/IN
ASD/NN
is/VBZ
still/RB
largely/RB
unknown/JJ
./.
====================
Growing/VBG
evidence/NN
has/VBZ
suggested/VBN
a/DT
genetic/JJ
background/NN
of/IN
ASD/NN
development/NN
./.
====================
The/DT
concordance/NN
rates/NNS
of/IN
ASD/NN
in/IN
monozygotic/JJ
twins/NNS
were/VBD
reported/VBN
to/TO
be/VB
significantly/RB
higher/JJR
than/IN
in/IN
dizygotic/JJ
twins/NNS
,/,
and/CC
the/DT
recurrence/NN
rates/NNS
in/IN
siblings/NNS
are/VBP
approximately/RB
10/CD
times/NNS
higher/JJR
than/IN
in/IN
the/DT
normal/JJ
population/NN
(/(
Folstein/NN
and/CC
RosenSheidley/NNP
,/,
2001/CD
)/)
./.
====================
Cytogenetic/JJ
alterations/NNS
were/VBD
detected/VBN
in/IN
7.4/CD
%/NN
of/IN
ASDs/NNS
(/(
Vorstman/JJ
et/FW
al./FW
,/,
2006/CD
)/)
,/,
and/CC
some/DT
alterations/NNS
have/VBP
been/VBN
suggested/VBN
as/IN
causative/JJ
factors/NNS
of/IN
neurodevelopmental/JJ
disorders/NNS
(/(
Merikangas/NNS
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Several/JJ
studies/NNS
have/VBP
revealed/VBN
that/IN
ASDs/NNS
are/VBP
associated/VBN
with/IN
genetic/JJ
factors/NNS
,/,
such/JJ
as/IN
single/JJ
gene/NN
disorders/NNS
and/CC
genetic/JJ
polymorphisms/NNS
,/,
including/VBG
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
and/CC
copy/NN
number/NN
variation/NN
(/(
CNV/NN
)/)
,/,
and/CC
that/IN
multiple/JJ
genetic/JJ
factors/NNS
may/MD
work/VB
together/RB
(/(
McCauley/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Santangelo/NNP
and/CC
Tsatsanis/FW
,/,
2005/CD
)/)
./.
====================
Significant/JJ
associations/NNS
have/VBP
been/VBN
reported/VBN
between/IN
ASDs/NNS
and/CC
CNVs/NNS
of/IN
various/JJ
genes/NNS
,/,
such/JJ
as/IN
NLGN3/NN
(/(
Xq13.1/NN
)/)
,/,
NLGN4/NN
(/(
Xp22.23/NN
)/)
,/,
SHANK3/NN
(/(
22q13.3/CD
)/)
,/,
and/CC
NRXN1/NN
(/(
2p16.3/CD
)/)
(/(
Christian/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Cook/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
However/RB
,/,
most/JJS
of/IN
these/DT
candidate/NN
genes/NNS
have/VBP
been/VBN
neither/CC
successfully/RB
replicated/VBN
in/IN
independent/JJ
study/NN
populations/NNS
nor/CC
functionally/RB
validated/VBN
as/IN
susceptible/JJ
genes/NNS
or/CC
loci/NNS
./.
====================
Maintaining/JJ
neuronal/JJ
cellular/JJ
connectivity/NN
as/IN
well/RB
as/IN
synaptogenesis/NN
has/VBZ
been/VBN
suggested/VBN
to/TO
play/VB
a/DT
role/NN
in/IN
the/DT
pathologensis/NN
of/IN
ASD/NN
by/IN
trafficking/VBG
of/IN
immune/JJ
cells/NNS
and/CC
mediators/NNS
through/IN
astroglial/JJ
and/CC
microglial/JJ
cells/NNS
(/(
Gupta/NNP
,/,
2000/CD
)/)
./.
====================
T/NN
cell/NN
receptor/NN
beta/NN
affects/VBZ
TCR/NN
signaling/NN
and/CC
T/NN
cell/NN
polarity/NN
(/(
McKinney/NNP
et/FW
al./FW
,/,
2010/CD
)/)
,/,
which/WDT
consequently/RB
affect/VB
neuronal/JJ
activity/NN
,/,
development/NN
,/,
and/CC
plasticity/NN
(/(
Syken/NN
and/CC
Shatz/NN
,/,
2003/CD
)/)
./.
====================
Several/JJ
association/NN
studies/NNS
reported/VBD
that/IN
an/DT
imbalance/NN
of/IN
the/DT
CD4＋/JJ
:/:
CD8＋/NN
T/NN
cell/NN
ratio/NN
was/VBD
found/VBN
in/IN
children/NN
with/IN
ASDs/NNS
(/(
Denny/NNP
et/FW
al./FW
,/,
1996/CD
;/:
Sweeten/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Another/DT
interesting/VBG
clue/NN
to/TO
connect/VB
the/DT
TCR/NN
with/IN
ASD/NN
is/VBZ
that/IN
the/DT
7q34-35/NN
region/NN
,/,
where/WRB
the/DT
T/NN
cell/NN
receptor/NN
B/NN
variable/JJ
region/NN
(/(
TCRB/NN
)/)
is/VBZ
located/JJ
,/,
was/VBD
found/VBN
to/TO
be/VB
rearranged/VBN
in/IN
a/DT
patient/NN
with/IN
mental/JJ
retardation/NN
,/,
anxiety/DT
disorder/NN
,/,
and/CC
autistic/JJ
features/NNS
(/(
Dauwerse/JJ
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
In/IN
previous/JJ
reports/NNS
,/,
the/DT
7q31-34/NN
(/(
Risch/NNP
et/FW
al./FW
,/,
1999/CD
)/)
and/CC
7q32.3-36.3/NN
(/(
Schanen/NNP
,/,
2006/CD
)/)
regions/NNS
showed/VBD
association/NN
with/IN
mental/JJ
retardation/NN
and/CC
ASD/NN
phenotypic/JJ
features/NNS
(/(
Dauwerse/JJ
et/FW
al./FW
,/,
2010/CD
;/:
Gu/NNP
and/CC
Lupski/NNP
,/,
2008/CD
)/)
./.
====================
Based/VBN
on/IN
these/DT
reports/NNS
,/,
it/PRP
seems/VBZ
that/DT
TCRB/NN
may/MD
affect/VB
the/DT
susceptibility/NN
to/TO
neurodevelopmental/JJ
disorders/NNS
,/,
including/VBG
ASD/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyzed/VBD
163/CD
ASD/NN
subjects/NNS
and/CC
97/CD
normal/JJ
controls/NNS
by/IN
genomic/JJ
quantitative/JJ
PCR/NN
(/(
qPCR/NN
)/)
to/TO
evaluate/VB
the/DT
association/NN
between/IN
the/DT
7q34/NN
locus/NN
,/,
harboring/VBG
the/DT
TCRB/NN
region/NN
,/,
and/CC
ASDs/NNS
and/CC
the/DT
potential/JJ
diagnostic/JJ
usefulness/NN
of/IN
TCRB/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
We/PRP
recruited/VBD
163/CD
ASD/NN
children/NN
(/(
137/CD
boys/NNS
and/CC
26/CD
girls/VBZ
)/)
who/WP
were/VBD
diagnosed/VBN
with/IN
ASD/NN
from/IN
the/DT
Department/JJ
of/IN
Child/JJ
Psychiatry/NN
of/IN
Gyeongsang/JJ
National/JJ
University/NN
Hospital/JJ
,/,
Ghil/NN
Hospital/JJ
and/CC
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
./.
====================
Each/DT
proband/CC
with/IN
ASD/NN
was/VBD
initially/RB
screened/VBN
by/IN
two/CD
board-certified/VBN
child/JJ
psychiatrists/NNS
according/VBG
to/TO
DSM-IV/NN
criteria/NNS
(/(
American/NNP
Psychiatric/JJ
Association/NN
,/,
1994/CD
)/)
and/CC
assessed/VBN
using/VBG
the/DT
Autism/NN
Diagnostic/JJ
Interview/NN
Revised/JJ
(/(
ADIR/NN
)/)
and/CC
the/DT
Korean/JJ
version/NN
of/IN
the/DT
Autism/NN
Diagnostic/JJ
Observation/NN
Schedule/NN
(/(
ADOS/NN
)/)
./.
====================
Probands/NNS
with/IN
chromosomal/JJ
abnormalities/NNS
,/,
such/JJ
as/IN
fragile/JJ
X/NN
syndrome/NN
or/CC
other/JJ
neurological/JJ
or/CC
medical/JJ
conditions/NNS
suspected/VBD
to/TO
be/VB
associated/VBN
with/IN
ASDs/NNS
,/,
were/VBD
not/RB
included/VBN
./.
====================
All/DT
parents/NNS
or/CC
legal/JJ
guardians/NNS
of/IN
probands/NNS
provided/VBD
written/CD
informed/VBN
consent/NN
for/IN
participation/NN
in/IN
this/DT
study/NN
./.
====================
The/DT
normal/JJ
control/JJ
samples/NNS
consisted/VBD
of/IN
97/CD
Korean/JJ
adult/JJ
males/NNS
who/WP
were/VBD
free/JJ
of/IN
any/DT
psychiatric/JJ
or/CC
congenital/JJ
disorders/NNS
./.
====================
This/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Boards/NNS
of/IN
the/DT
participating/VBG
institutions/NNS
./.
====================
To/TO
search/VB
the/DT
CNV/NN
region/NN
relevant/JJ
to/TO
ASD/NN
,/,
the/DT
Autism/NN
Chromosome/NN
Rearrangement/JJ
Database/NN
(/(
ACRD/NN
)/)
inn/JJ
the/DT
database/NN
of/IN
Genome/NN
Variants/NNS
(/(
http/NN
:/:
//projects/NNS
./.
====================
tcag/DT
./.
====================
ca//RB
autism//JJ
)/)
,/,
the/DT
autism/NN
gene/NN
database/NN
AuDB/NN
(/(
http/NN
:/:
///CD
www/NN
./.
====================
mindspec/JJ
./.
====================
org/autdb/NN
./.
====================
html/NN
)/)
,/,
and/CC
the/DT
UCSC/NN
genome/NN
browser/JJR
(/(
http/NN
:/:
//www/JJ
./.
====================
genome/NN
./.
====================
ucsc/IN
./.
====================
edu//RB
)/)
were/VBD
used/VBN
./.
====================
We/PRP
selected/VBD
TCRB/NN
on/IN
the/DT
7q34/NN
region/NN
as/IN
the/DT
candidate/NN
region/NN
,/,
based/VBN
on/IN
an/DT
association/NN
between/IN
ASD/NN
and/CC
immunity/NN
through/IN
a/DT
literature/NN
analysis/NN
,/,
compared/VBN
it/PRP
with/IN
a/DT
database/NN
of/IN
genomic/JJ
variants/NNS
,/,
and/CC
chose/NN
the/DT
primer/NN
set/NN
by/IN
in/FW
silico/JJ
PCR/NN
in/IN
the/DT
UCSC/NN
browser/JJR
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
selected/VBN
region/NN
is/VBZ
located/JJ
on/IN
the/DT
TCRB/NN
gene/NN
cluster/NN
,/,
and/CC
it/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
there/EX
are/VBP
many/JJ
CNVs/NNS
and/CC
duplication/NN
sites/NNS
(/(
Redon/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
The/DT
primer/NN
sequences/NNS
(/(
141,702,316-141,702,404/CD
;/:
NCBI/NNP
build/JJ
36/CD
)/)
of/IN
the/DT
target/NN
region/NN
are/VBP
as/IN
follows/VBZ
:/:
5'-TGAGGCAGCCTGT/JJ
GTGCTTTACTA-3/NN
'/``
for/IN
forward/JJ
and/CC
5'-TAGGCTACACATGCCCTGCTACAA3/NN
'/``
for/IN
reverse/JJ
./.
====================
As/IN
a/DT
diploid/JJ
internal/JJ
reference/RB
gene/NN
for/IN
genomic/JJ
qPCR/NN
,/,
a/DT
gene/NN
encoding/VBG
heparan/NN
sulfate/NN
,/,
6-O-/JJ
sulfotransferase/NN
3/CD
(/(
HS6ST3/NN
)/)
,/,
was/VBD
used/VBN
,/,
because/IN
neither/CC
CNV/NN
nor/CC
segmental/JJ
duplication/NN
in/IN
this/DT
gene/NN
has/VBZ
been/VBN
observed/VBN
,/,
according/VBG
to/TO
the/DT
Database/NN
of/IN
Genomic/JJ
Variants/NNS
./.
====================
The/DT
primer/NN
sequences/NNS
for/IN
the/DT
internal/JJ
control/JJ
are/VBP
as/IN
follows/VBZ
:/:
5'-CGCTACCACCACACCAAGCAG-3/CD
'/``
for/IN
forward/JJ
and/CC
5'-CCACCTGGCTGTTGTAGTCCTC-3/NN
'/``
for/IN
reverse/JJ
./.
====================
Genomic/JJ
qPCR/NN
was/VBD
performed/VBN
using/VBG
the/DT
Mx3000P/NN
qPCR/NN
system/NN
(/(
Stratagene/NN
,/,
La/NN
Jolla/NN
,/,
CA/NN
)/)
./.
====================
Twenty/CD
microliters/NNS
of/IN
real-time/JJ
qPCR/NN
mixture/NN
contained/VBD
20/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
,/,
SYBR/NN
Premix/JJ
(/(
FINNZYMES/NN
,/,
Finland/CC
)/)
,/,
1×/CD
ROX/NN
,/,
and/CC
10/CD
pmol/NN
primers/NNS
./.
====================
Thermal/JJ
cycling/NN
conditions/NNS
consisted/VBD
of/IN
one/CD
hot/JJ
start/NN
cycle/NN
of/IN
10/CD
min/NN
at/IN
95oC/JJ
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
of/IN
5/CD
sec/NN
at/IN
95oC/JJ
,/,
10/CD
sec/JJ
at/IN
55oC/JJ
,/,
and/CC
20/CD
sec/JJ
at/IN
72oC/JJ
./.
====================
After/IN
the/DT
PCR/NN
reactions/NNS
,/,
melting/VBG
curve/NN
analysis/NN
was/VBD
performed/VBN
to/TO
confirm/VB
specific/JJ
amplification/NN
./.
====================
NA10851/NN
DNA/NN
(/(
Coriell/NN
,/,
Camden/JJ
,/,
NJ/NN
,/,
USA/NN
)/)
was/VBD
used/VBN
as/IN
a/DT
calibrator/NN
./.
====================
All/DT
qPCR/NN
experiments/NNS
were/VBD
performed/VBN
in/IN
triplicate/NN
,/,
and/CC
amplification/NN
efficiencies/NNS
for/IN
both/DT
the/DT
target/NN
and/CC
internal/JJ
reference/VBP
genes/NNS
were/VBD
evaluated/VBN
using/VBG
a/DT
standard/JJ
curve/JJ
over/IN
serial/JJ
1:5/CD
dilutions/NNS
using/VBG
MxPro/JJ
Version/NN
3.00/CD
software/RB
./.
====================
To/TO
assess/VB
efficiency/NN
of/IN
PCR/NN
amplification/NN
,/,
the/DT
Ct/JJ
value/NN
was/VBD
determined/VBN
at/IN
the/DT
cycle/NN
at/IN
which/WDT
the/DT
amplicon/NN
of/IN
HS6ST3/NN
attained/VBD
the/DT
threshold/JJ
of/IN
the/DT
standard/JJ
curve/NN
./.
====================
Relative/JJ
copy/NN
number/NN
was/VBD
calculated/VBN
by/IN
the/DT
ΔΔCt/JJ
method/NN
using/VBG
the/DT
Ct/JJ
values/NNS
,/,
as/IN
described/VBN
elsewhere/RB
(/(
Yim/NN
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
The/DT
copy/NN
number/NN
for/IN
TCRB/NN
was/VBD
defined/VBN
as/IN
2−ΔΔCt/JJ
,/,
where/WRB
ΔCt/JJ
is/VBZ
the/DT
difference/NN
in/IN
threshold/JJ
cycles/NNS
for/IN
the/DT
sample/JJ
in/IN
question/NN
,/,
normalized/VBN
against/IN
a/DT
reference/NN
gene/NN
(/(
HS6ST3/NN
)/)
and/CC
expressed/VBD
relative/JJ
to/TO
the/DT
value/NN
obtained/VBN
by/IN
NA10851/NN
DNA/NN
(/(
individual/NA10851/LS
)/)
./.
====================
We/PRP
assumed/VBD
the/DT
median/JJ
value/NN
of/IN
the/DT
TCRB/NN
qPCR/NN
ratios/NNS
in/IN
the/DT
normal/JJ
control/JJ
group/NN
to/TO
be/VB
diploid/JJ
and/CC
adjusted/VBN
all/DT
measured/VBN
TCRB/NN
qPCR/NN
ratio/NN
values/NNS
accordingly/RB
./.
====================
Then/RB
,/,
the/DT
adjusted/JJ
ratio/NN
values/NNS
were/VBD
rounded/VBN
off/IN
to/TO
the/DT
nearest/JJ
integer/NN
./.
====================
Statistical/JJ
procedures/NNS
were/VBD
performed/VBN
using/VBG
Stata/NN
software/JJ
(/(
version/NN
10.0/CD
;/:
Stata/NNS
Corporation/NN
,/,
College/NN
station/NN
,/,
TX/NN
,/,
USA/NN
)/)
./.
====================
The/DT
χ2test/JJS
was/VBD
used/VBN
to/TO
test/VB
allelic/JJ
differences/NNS
between/IN
the/DT
case/NN
and/CC
control/NN
groups/NNS
./.
====================
p＜0.05/NN
was/VBD
considered/VBN
to/TO
be/VB
statistically/RB
significant/JJ
./.
====================
All/DT
measured/VBN
copy/NN
number/NN
ratio/NN
values/NNS
in/IN
TCRB/NN
and/CC
the/DT
controls/NNS
were/VBD
converted/VBN
to/TO
integers/NNS
,/,
as/IN
described/VBN
above/IN
./.
====================
There/EX
was/VBD
no/DT
significant/JJ
difference/NN
in/IN
the/DT
frequency/NN
distribution/NN
of/IN
TCRB/NN
copy/NN
number/NN
between/IN
ASD/NN
cases/NNS
and/CC
normal/JJ
controls/NNS
./.
====================
As/IN
shown/VBN
in/IN
Table/JJ
1/CD
,/,
TCRB/NN
copy/NN
numbers/NNS
ranged/VBD
from/IN
0/CD
to/TO
5/CD
copies/NNS
,/,
and/CC
the/DT
frequency/NN
distribution/NN
of/IN
each/DT
copy/NN
number/NN
was/VBD
similar/JJ
between/IN
the/DT
two/CD
groups/NNS
./.
====================
The/DT
proportion/NN
of/IN
individuals/NNS
with/IN
＜2/NN
copies/NNS
of/IN
TCRB/NN
was/VBD
52.8/CD
%/NN
(/(
86/163/CD
)/)
in/IN
ASD/NN
cases/NNS
and/CC
57.1/CD
%/NN
(/(
52/97/CD
)/)
in/IN
the/DT
control/NN
group/NN
(/(
pvalue=/JJ
0.44/CD
)/)
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
proportion/NN
of/IN
individuals/NNS
with/IN
＞2/NN
copies/NNS
of/IN
TCRB/NN
was/VBD
11.7/CD
%/NN
(/(
19/163/CD
)/)
in/IN
ASD/NN
cases/NNS
and/CC
12.1/NN
%/NN
(/(
11/91/CD
)/)
in/IN
the/DT
control/NN
group/NN
(/(
p-value=0.68/NN
)/)
./.
====================
To/TO
estimate/VB
the/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
of/IN
ASD/NN
,/,
we/PRP
chose/VBP
the/DT
diploid/JJ
copy/NN
number/NN
group/NN
as/IN
a/DT
reference/NN
point/NN
./.
====================
After/IN
the/DT
effects/NNS
of/IN
sex/NN
were/VBD
adjusted/VBN
by/IN
logistic/JJ
regression/NN
,/,
ORs/NNS
for/IN
individuals/NNS
with/IN
＜2/NN
copies/NNS
or/CC
＞2/NN
copies/NNS
showed/VBD
no/DT
significant/JJ
difference/NN
compared/VBN
with/IN
the/DT
diploid/JJ
copy/NN
number/NN
as/IN
reference/RB
(/(
n=2/NN
)/)
./.
====================
Since/IN
the/DT
age/NN
variable/JJ
showed/VBD
a/DT
strong/JJ
colinearity/NN
with/IN
the/DT
casecontrol/NN
status/NN
,/,
only/RB
the/DT
effect/NN
of/IN
sex/NN
was/VBD
adjusted/VBN
through/IN
logistic/JJ
regression/NN
./.
====================
The/DT
adjusted/JJ
OR/NN
was/VBD
also/RB
insignificant/JJ
(/(
1.05/CD
,/,
95/CD
%/NN
CI/NN
0.80-1.38/CD
)/)
./.
====================
Immunological/JJ
dysfunction/NN
has/VBZ
been/VBN
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
ASD/NN
(/(
Folstein/NN
and/CC
RosenSheidley/NNP
,/,
2001/CD
;/:
Rutter/NN
,/,
2005/CD
)/)
./.
====================
Especially/RB
,/,
T/NN
cellmediated/JJ
immunity/NN
has/VBZ
been/VBN
considered/VBN
important/JJ
for/IN
the/DT
development/NN
of/IN
ASD/NN
(/(
Cohly/RB
and/CC
Panja/NN
,/,
2005/CD
)/)
./.
====================
To/TO
maintain/VB
immune/JJ
balance/NN
against/IN
numerous/JJ
MHC/NN
molecules/NNS
in/IN
the/DT
central/JJ
nervous/JJ
system/NN
,/,
the/DT
rejoining/VBG
of/IN
the/DT
TCR/NN
plays/VBZ
a/DT
role/NN
in/IN
T/NN
cell/NN
responses/NNS
./.
====================
In/IN
autistic/JJ
children/NN
and/CC
their/PRP$
families/NNS
,/,
autoimmune/JJ
disorders/NNS
,/,
such/JJ
as/IN
asthma/NN
,/,
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
more/RBR
common/JJ
than/IN
in/IN
the/DT
normal/JJ
population/NN
(/(
van/NN
Gent/JJ
et/FW
al./FW
,/,
1997/CD
)/)
./.
====================
Also/RB
,/,
elevated/JJ
levels/NNS
of/IN
IFN-γ/JJ
in/IN
postmortem/NN
autistic/JJ
patients/NNS
have/VBP
suggested/VBN
a/DT
possible/JJ
association/NN
between/IN
the/DT
pathogenesis/NN
of/IN
ASDs/NNS
and/CC
impairment/JJ
of/IN
T/NN
cell-mediated/JJ
immunity/NN
(/(
Vargas/NNS
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Although/IN
CNV/NN
has/VBZ
been/VBN
suggested/VBN
as/IN
a/DT
new/JJ
type/NN
of/IN
genomic/JJ
diversity/NN
among/IN
normal/JJ
individuals/NNS
,/,
including/VBG
Koreans/NNS
(/(
Freeman/JJ
et/FW
al./FW
,/,
2006/CD
;/:
Yim/NN
et/FW
al./FW
,/,
2010/CD
)/)
,/,
it/PRP
also/RB
seems/VBZ
to/TO
play/VB
a/DT
certain/JJ
role/NN
in/IN
disease/NN
susceptibility/NN
./.
====================
A/DT
number/NN
of/IN
significant/JJ
CNVs/NNS
on/IN
chromosome/NN
7/CD
and/CC
15/CD
have/VBP
been/VBN
suggested/VBN
to/TO
be/VB
associated/VBN
with/IN
ASD/NN
(/(
Marshall/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
In/IN
addition/NN
,/,
among/IN
copy/NN
number/NN
alterations/NNS
,/,
changes/NNS
on/IN
chromosome/NN
7/CD
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
various/JJ
psychiatric/JJ
diseases/NNS
,/,
such/JJ
as/IN
ASD/NN
and/CC
mental/JJ
retardation/NN
./.
====================
For/IN
example/NN
,/,
complex/NN
rearrangements/NNS
on/IN
chromosome/NN
7q/NN
were/VBD
identified/VBN
in/IN
patients/NNS
with/IN
mental/JJ
retardation/NN
,/,
anxiety/NN
disorder/NN
,/,
and/CC
autistic/JJ
features/NNS
(/(
Dauewerse/NN
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
One/CD
of/IN
the/DT
key/JJ
ASD-associated/JJ
genes/NNS
,/,
named/VBN
CNTNAP2/NN
,/,
is/VBZ
located/JJ
on/IN
7q35/NN
(/(
Arking/NN
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Our/PRP$
target/NN
locus/NN
is/VBZ
a/DT
variable/JJ
region/NN
in/IN
TCRB/NN
./.
====================
Abnormalities/NNS
in/IN
TCRB/NN
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
immunological/JJ
defects/NNS
(/(
Currier/NN
et/FW
al./FW
,/,
1998/CD
;/:
Zhao/NNP
et/FW
al./FW
,/,
1994/CD
)/)
./.
====================
Based/VBN
on/IN
the/DT
previous/JJ
findings/NNS
described/VBN
above/IN
,/,
we/PRP
hypothesized/VBD
that/IN
the/DT
CNV/NN
of/IN
the/DT
TCRB/NN
gene/NN
,/,
located/JJ
on/IN
7q34/NN
,/,
may/MD
be/VB
associated/VBN
with/IN
ASDs/NNS
./.
====================
We/PRP
explored/VBD
this/DT
possibility/NN
by/IN
genomic/JJ
qPCR/NN
,/,
targeting/VBG
the/DT
TCRB/NN
gene/NN
,/,
but/CC
we/PRP
did/VBD
not/RB
find/VB
any/DT
evidence/NN
of/IN
association/NN
./.
====================
There/EX
are/VBP
several/JJ
limitations/NNS
of/IN
this/DT
study/NN
./.
====================
First/RB
,/,
we/PRP
examined/VBD
one/CD
locus/NN
to/TO
quantify/VB
the/DT
DNA/NN
copy/NN
number/NN
dosage/NN
of/IN
TCRB/NN
(/(
7q34/CD
)/)
./.
====================
To/TO
represent/VB
the/DT
copy/NN
number/NN
status/NN
of/IN
this/DT
gene/NN
more/RBR
reliably/RB
,/,
several/JJ
more/RBR
qPCR/NN
probes/NNS
must/MD
be/VB
examined/VBN
in/IN
the/DT
same/JJ
study/NN
subjects/NNS
./.
====================
Second/RB
,/,
the/DT
study/NN
size/NN
was/VBD
not/RB
large/JJ
enough/IN
to/TO
make/VB
a/DT
definite/JJ
conclusion/NN
./.
====================
In/IN
conclusion/NN
,/,
there/EX
was/VBD
no/DT
significant/JJ
difference/NN
in/IN
TCRB/NN
gene/NN
copy/NN
number/NN
between/IN
ASDs/NNS
and/CC
normal/JJ
individuals/NNS
./.
====================
An/DT
additional/JJ
SNP/NN
analysis/NN
might/MD
be/VB
useful/JJ
and/CC
add/VBP
some/DT
more/RBR
information/NN
./.
====================
Although/IN
we/PRP
could/MD
not/RB
see/VB
a/DT
positive/JJ
association/NN
,/,
our/PRP$
results/NNS
will/MD
be/VB
valuable/JJ
information/NN
for/IN
mining/JJ
ASDassociated/JJ
genes/NNS
and/CC
for/IN
exploring/VBG
the/DT
role/NN
of/IN
T/NN
cell/NN
immunity/NN
further/RBR
in/IN
the/DT
pathogenesis/NN
of/IN
ASD/NN
./.
====================
